Evaluation of immunogenicity and efficacy of combined DNA and adjuvanted protein vaccination in a human immunodeficiency virus type 1/murine leukemia virus pseudotype challenge model

Vaccine

Volumn 25, Issue 11, 2007, Pages 2145-2154

  Rollman, Erik ^a   Mathy, Nathalie ^b,c   Bråve, Andreas ^a   Boberg, Andreas ^a   Kjerrström, Anne ^a   van Wely, Cathy ^b   Engström, Gunnel ^a   Johansson, Susanne ^a   Aperia, Kajsa ^a   Eriksson, Lars E ^a   Benthin, Reinhold ^a   Ertl, Peter ^b   Heeney, Jonathan ^d   Hinkula, Jorma ^a,e   Voss, Gerald ^c   Wahren, Britta ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b GLAXOSMITHKLINE   (United Kingdom)

^c GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^d BIOMEDICAL PRIMATE RESEARCH CENTRE   (Netherlands)

^e LINKÖPING UNIVERSITY   (Sweden)

Author keywords

AS02A; Env; HIV 1; HIV MuLV; Nef; Prime boost; Small animal model; Tat

Indexed keywords

ANTIGEN; AS02A ADJUVANT; CD8 ANTIGEN; DNA VACCINE; IMMUNOLOGICAL ADJUVANT; PLASMID DNA; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLEARANCE; CONTROLLED STUDY; DRUG EFFICACY; ENVELOPE GENE; ENZYME LINKED IMMUNOSPOT ASSAY; GENE GUN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; MOUSE; MURINE LEUKEMIA VIRUS; NEF GENE; NONHUMAN; PRIORITY JOURNAL; TAT GENE; VACCINATION; VIRUS GENE; VIRUS REPLICATION; VIRUS TYPING;

ADJUVANTS, IMMUNOLOGIC; AIDS VACCINES; ANIMALS; BIOLISTICS; DISEASE MODELS, ANIMAL; DRUG COMBINATIONS; HIV ANTIBODIES; HIV ANTIGENS; HIV INFECTIONS; HIV-1; HUMANS; IMMUNIZATION, SECONDARY; INJECTIONS, INTRAMUSCULAR; LEUKEMIA VIRUS, MURINE; LIPID A; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; RECOMBINANT PROTEINS; RETROVIRIDAE INFECTIONS; SAPONINS; T-LYMPHOCYTES; TUMOR VIRUS INFECTIONS; VACCINATION; VACCINES, DNA; VACCINES, SUBUNIT;

EID: 33846862917     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.10.057     Document Type: Article

References (37)

1. UNAIDS/WHO. NAIDS 2005 Report on the global AIDS epidemic. UNAIDS/WHO; 2005.
2. McMichael A.J., and Hanke T. HIV vaccines 1983-2003. Nat Med 9 7 (2003) 874-880
3. Donnelly J.J., Wahren B., and Liu M.A. DNA vaccines: progress and challenges. J Immunol 175 2 (2005) 633-639
4. Nabel G.J. HIV vaccine strategies. Vaccine 20 15 (2002) 1945-1947
5. Mooij P., and Heeney J.L. Rational development of prophylactic HIV vaccines based on structural and regulatory proteins. Vaccine 20 3-4 (2001) 304-321
6. Mascola J.R. Passive transfer studies to elucidate the role of antibody-mediated protection against HIV-1. Vaccine 20 15 (2002) 1922-1925
7. Dumais N., Patrick A., Moss R.B., Davis H.L., and Rosenthal K.L. Mucosal immunization with inactivated human immunodeficiency virus plus CpG oligodeoxynucleotides induces genital immune responses and protection against intravaginal challenge. J Infect Dis 186 8 (2002) 1098-1105
8. Osterhaus A., de Vries P., Morein B., Akerblom L., and Heeney J. Comparison of protection afforded by whole virus ISCOM versus MDP adjuvanted formalin-inactivated SIV vaccines from IV cell-free or cell-associated homologous challenge. AIDS Res Hum Retroviruses 8 8 (1992) 1507-1510
9. Beattie T., Rowland-Jones S., and Kaul R. HIV-1 and AIDS: what are protective immune responses?. J HIV Ther 7 2 (2002) 35-39
10. Tritel M., Stoddard A.M., Flynn B.J., Darrah P.A., Wu C.Y., Wille U., et al. Prime-boost vaccination with HIV-1 Gag protein and cytosine phosphate guanosine oligodeoxynucleotide, followed by adenovirus, induces sustained and robust humoral and cellular immune responses. J Immunol 171 5 (2003) 2538-2547
11. Newman M.J. Heterologous prime-boost vaccination strategies for HIV-1: augmenting cellular immune responses. Curr Opin Investig Drugs 3 3 (2002) 374-378
12. Rollman E., Hinkula J., Arteaga J., Zuber B., Kjerrstrom A., Liu M., et al. Multi-subtype gp160 DNA immunization induces broadly neutralizing anti-HIV antibodies. Gene Ther 11 14 (2004) 1146-1154
13. Amara R.R., Villinger F., Altman J.D., Lydy S.L., O'Neil S.P., Staprans S.I., et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292 5514 (2001) 69-74
14. Shiver J.W., Fu T.M., Chen L., Casimiro D.R., Davies M.E., Evans R.K., et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415 6869 (2002) 331-335
15. Voss G., Manson K., Montefiori D., Watkins D.I., Heeney J., Wyand M., et al. Prevention of disease induced by a partially heterologous AIDS virus in rhesus monkeys by using an adjuvanted multicomponent protein vaccine. J Virol 77 2 (2003) 1049-1058
16. Irwin M.J., Heath W.R., and Sherman L.A. Species-restricted interactions between CD8 and the alpha 3 domain of class I influence the magnitude of the xenogeneic response. J Exp Med 170 4 (1989) 1091-1101
17. Pascolo S., Bervas N., Ure J.M., Smith A.G., Lemonnier F.A., and Perarnau B. HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2. 1 monochain transgenic H-2Db beta2m double knockout mice. J Exp Med 185 12 (1997) 2043-2051
18. Asakura Y.H.J., Leandersson A.C., Fukushima J., Okuda K., and Wahren B. Induction of HIV-1 specific mucosal immune responses by DNA vaccination. Scand J Immunol 46 4 (1997) 326-330
19. Isaguliants M.G., Petrakova N.N., Zuber B., Pokrovskaya K., Gizatullin R., Kostyuk D.A., et al. DNA-encoding enzymatically active HIV-1 reverse transcriptase, but not the inactive mutant, confers resistance to experimental HIV-1 challenge. Intervirology 43 4-6 (2000) 288-293
20. Andang M., Hinkula J., Hotchkiss G., Larsson S., Britton S., Wong-Staal F., et al. Dose-response resistance to HIV-1/MuLV pseudotype virus ex vivo in a hairpin ribozyme transgenic mouse model. Proc Natl Acad Sci USA 96 22 (1999) 12749-12753
21. Spector D.H., Wade E., Wright D.A., Koval V., Clark C., Jaquish D., et al. Human immunodeficiency virus pseudotypes with expanded cellular and species tropism. J Virol 64 5 (1990) 2298-2308
22. Miller D.G., Edwards R.H., and Miller A.D. Cloning of the cellular receptor for amphotropic murine retroviruses reveals homology to that for gibbon ape leukemia virus. Proc Natl Acad Sci USA 91 1 (1994) 78-82
23. Ljungberg K., Rollman E., Eriksson L., Hinkula J., and Wahren B. Enhanced immune responses after DNA vaccination with combined envelope genes from different HIV-1 subtypes. Virology 302 1 (2002) 44-57
24. Spetz A.L., Sorensen A.S., Walther-Jallow L., Wahren B., Andersson J., Holmgren L., et al. Induction of HIV-1-specific immunity after vaccination with apoptotic HIV-1/murine leukemia virus-infected cells. J Immunol 169 10 (2002) 5771-5779
25. Hinkula J., Rollman E., Lundholm P., Benthin R., Okuda K., and Wahren B. Genetic immunization with multiple HIV-1 genes provides protection against HIV-1/MuLV pseudovirus challenge in vivo. Cells Tissues Organs 177 3 (2004) 169-184
26. Malm M., Rollman E., Ustav M., Hinkula J., Krohn K., Wahren B., et al. Cross-clade protection induced by human immunodeficiency virus-1 DNA immunogens expressing consensus sequences of multiple genes and epitopes from subtypes A, B, C, and FGH. Viral Immunol 18 4 (2005) 678-688
27. Sundqvist V.A., Albert J., Ohlsson E., Hinkula J., Fenyo E.M., and Wahren B. Human immunodeficiency virus type 1 p24 production and antigenic variation in tissue culture of isolates with various growth characteristics. J Med Virol 29 3 (1989) 170-175
28. McCormack S., Tilzey A., Carmichael A., Gotch F., Kepple J., Newberry A., et al. A phase I trial in HIV negative healthy volunteers evaluating the effect of potent adjuvants on immunogenicity of a recombinant gp120W61D derived from dual tropic R5X4 HIV-1ACH320. Vaccine 18 13 (2000) 1166-1177
29. Asakura Y., Lundholm P., Kjerrstrom A., Benthin R., Lucht E., Fukushima J., et al. DNA-plasmids of HIV-1 induce systemic and mucosal immune responses. Biol Chem 380 3 (1999) 375-379
30. Feltquate D.M., Heaney S., Webster R.G., and Robinson H.L. Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization. J Immunol 158 5 (1997) 2278-2284
31. Goepfert, P, Tomaras, G, Horton, H, Montefiori, D, Ferrari, G, Deers, M, et al. Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers. Vaccine 2006 August 10; [Epub ahead of print].
32. Levy J.A. The search for the CD8+ cell anti-HIV factor (CAF). Trends Immunol 24 12 (2003) 628-632
33. Pu R., Coleman J., Omori M., Arai M., Hohdatsu T., Huang C., et al. Dual-subtype FIV vaccine protects cats against in vivo swarms of both homologous and heterologous subtype FIV isolates. AIDS 15 10 (2001) 1225-1237
34. Nadas A., Zhong P., Burda S., Zekeng L., Urbanski M., Gorny M.K., et al. Defining human immunodeficiency virus (HIV) type 1 immunotypes with six human monoclonal antibodies. AIDS Res Hum Retroviruses 20 1 (2004) 55-65
35. Rollman E., Brave A., Boberg A., Gudmundsdotter L., Engstrom G., Isaguliants M., et al. The rationale behind a vaccine based on multiple HIV antigens. Microbes Infect 7 14 (2005) 1414-1423
36. Chakrabarti B.K., Ling X., Yang Z.Y., Montefiori D.C., Panet A., Kong W.P., et al. Expanded breadth of virus neutralization after immunization with a multiclade envelope HIV vaccine candidate. Vaccine 23 26 (2005) 3434-3445
37. Groenink M., Fouchier R.A., de Goede R.E., de Wolf F., Gruters R.A., Cuypers H.T., et al. Phenotypic heterogeneity in a panel of infectious molecular human immunodeficiency virus type 1 clones derived from a single individual. J Virol 65 4 (1991) 1968-1975